Clinical trials: Primary Hypertension, Grade 2
Pulmonary Hypertension
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to determine if treating patients suffering from moderate to severe pulmonary arterial hypertension with BSF 208075 will improve the patients' ability to exercise.
- Trial name
- NCT00046319
- Testing
- BSF 208075
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Grade I or II Essential Hypertension
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients…
- Trial name
- NCT02072330
- Testing
- TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide
- Where
- 13 sites in Japan
- Volunteers
- 353 people
- Sponsor
- Takeda
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Hypertension,Essential
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension…
- Trial name
- NCT03756103
- Testing
- SPH3127 tablet Dose 1, SPH3127 tablet Dose 2, SPH3127 tablet Dose 3
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
- Trial name
- NCT00262236
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 693 people
- Sponsor
- Novartis
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension
- Trial name
- NCT00413049
- Testing
- Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg
- Where
- 12 sites in China
- Volunteers
- 698 people
- Sponsor
- Novartis
Primary Mild and Moderate Hypertension
Study on Human Mass Balance of SPH3127 Tablets
To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and main excretion routes of radioactive…
- Trial name
- NCT05593562
- Testing
- SPH3127
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Essential Hypertension
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
- Trial name
- NCT07700875
- Testing
- QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 150 mg, QR01019 potassium salt 50 mg
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential…
- Trial name
- NCT00818883
- Testing
- Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
- Where
- 53 sites in United States, Russia
- Volunteers
- 609 people
- Sponsor
- Takeda
Hypertension
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)
Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
- Trial name
- NCT00400218
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks
- Volunteers
- 62 people
- Sponsor
- Organon and Co
Essential Hypertension
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
- Trial name
- OLMETREAT (NCT00311155)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Where
- 79 sites in Austria, Belgium and 7 more
- Volunteers
- 694 people
- Sponsor
- Sankyo Pharma Gmbh
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
- Trial name
- NCT00413413
- Testing
- Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg
- Where
- 19 sites in China
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922480
- Testing
- Fimasartan, Losartan (Control)
- Volunteers
- 506 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
- Trial name
- NCT01373086
- Testing
- LFF269, Eplerenone
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Essential Hypertension
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.
- Trial name
- NCT00328965
- Testing
- Lacidipine
- Sponsor
- GlaxoSmithKline
Hypertension
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved…
- Trial name
- NCT00147563
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Hypertension
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
- Trial name
- fimasartan (NCT01672476)
- Testing
- Valsartan, Fimasartan
- Where
- South Korea
- Volunteers
- 293 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension
- Trial name
- NCT02206659
- Testing
- Telmisartan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients
The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with amlodipine or felodipine alone.
- Trial name
- NCT00392262
- Testing
- valsartan + amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 224 people
- Sponsor
- Novartis